Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC). Background: Motesanib is an oral inhibitor of VEGF, PDFG, and Kit ...
Please provide your email address to receive an email when new articles are posted on . The phase 3 randomized study, presented at ASCO Annual Meeting, evaluated the overall response rate of ...
Racial disparity trends in clinical presentation and outcomes in colorectal cancer: Findings from an urban university hospital. Background: A combination of leucovorin (LV) and fluorouracil (FU) with ...
The authors say delivering FOLFOX via transarterial infusion could be a “perfect option for treating intrahepatic cholangiocarcinoma before patients receive targeted therapy, immunotherapy, or ...
Researchers found the application of FOLFOXai, an artificial intelligence (AI)–based predictor of response to FOLFOX chemotherapy in metastatic colorectal cancer (mCRC), may lead to improved treatment ...
SEQUOIA compared efficacy and safety of adding pegilodecakin (PEG), a pegylated recombinant human interleukin (IL)-10, with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) in patients following ...
Aprepitant, palonosetron and dexamethasone curbed chemotherapy-induced nausea and vomiting in certain women with gastrointestinal cancers who were receiving FOLFIRI or FOLFOX regimens. A combination ...
Roche Release: Results Show XELOX Provides Equivalent Overall Patient Survival Compared To FOLFOX In Advanced Colorectal Cancer NUTLEY, N.J., Jan. 22 -- Overall survival results from an international, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results